Tao Fu, Attovia Therapeutics CEO
May 9, 2024 07:30 AM EDT
Financing
Startups

At­tovia reels in $105M from crossover in­vestors to run mul­ti­ple tri­als of I&I bi­o­log­ics

Kyle LaHucik

Senior Reporter

Cal­i­for­nia biotech At­tovia Ther­a­peu­tics is back with a $105 mil­lion Se­ries B just 11 months af­ter un­veil­ing with $60 mil­lion.

The Fre­mont …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times